Indefinite Delivery Contract 75N93021D00013
Award Date
10/15/20
Last Date to Order
10/14/27
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
The University Of Iowa
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC Category
AN81 - R&D- Medical: Aids Research (Basic Research)
Federal Contract Vehicle
Pricing Type
Cost No Fee
Legislative Mandate
Employment Eligibility Verification
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a single-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Lovelace Biomedical Research Institute to provide preclinical development support for candidate products and drug development activities for HIV, hepatitis, and tuberculosis. The 7-year, $107.3 million contract covers a range of services across seven task areas, including in vitro screening,...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded this multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract to provide preclinical development support for candidate products and drug development activities related to HIV, hepatitis B, hepatitis C, and tuberculosis. The $107.3 million contract has a 7-year period of performance and encompasses seven task areas, including in vitro testing, synthesis of...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency of the U.S. Department of Health and Human Services, has awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract worth up to $107,274,471 to provide preclinical development support for candidate products and drug development activities related to HIV, hepatitis B and C, and tuberculosis. This multiple-award IDIQ contract has a 7-year period of performance from October 2020 to October 2027. The scope...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the U.S. Department of Health and Human Services, awarded a multiple award Indefinite Delivery/Indefinite Quantity (IDIQ) contract to provide preclinical development support for candidate products and drug development activities ranging from initial product discovery to activities required for clinical trials and product licensure. The $107.3 million contract has a 7-year period of performance from October...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, awarded this $107,274,471 Indefinite Delivery/Indefinite Quantity (IDIQ) contract to the University of North Carolina at Chapel Hill (UNC-CH) to provide preclinical development support for candidate products and drug development activities related to infectious diseases like HIV, hepatitis, and tuberculosis. The contract encompasses a wide range of services including in...
The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract to Sri International to provide preclinical development support for candidate products and drug development activities. The $107.3M contract has a 7-year period of performance from October 2020 to October 2027. The contract encompasses a broad scope of work, including in vitro testing and screening, small...
The University of Iowa was awarded a multiple-award indefinite delivery contract by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to provide contract research organization (CRO) support for drug product development, manufacturing, and stability studies. The contract has a ceiling value of $14,444,775 and a period of performance through July 2024. Under this IDIQ contract, the University of Iowa has received two...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products addressing HIV, HBV, HCV, and Mycobacterium tuberculosis. The total potential value of the IDV is $107,274,471 over seven years ending October 2027. Task orders have been issued under several areas. Lovelace Biomedical Research Institute received a $18,397 order to develop...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products addressing HIV, HBV, HCV, and Mycobacterium tuberculosis. Valued at up to $107 million over seven years, the contracts authorize task orders across seven areas including in vitro testing, synthesis of therapeutic agents, small animal models, formulation development,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a single-award Indefinite Delivery Contract (IDC) worth up to $146.3M to the University of South Alabama to provide pre-clinical models of infectious diseases. The contract has a 7-year ordering period ending on July 14, 2031. The IDC comprises four task areas focused on developing and refining small animal, non-human primate, and non-traditional/animal replacement models to evaluate candidate countermeasures (e.g....